Approval · Notice of Compliance 25223 · 2021
ELAPRASE: Notice of Compliance 25223
Issued February 11, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25223
- Date
- February 11, 2021
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ELAPRASE | Not yet assigned | — |
Medicinal ingredients
- IDURSULFASE 2 MG per ML